Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Satoru Asahi"'
Autor:
Kaori Ishikawa, Yuu Moriya, Yoshihiko Tagawa, Takahiro Kondo, Joost DeJongh, Satoru Asahi, Akifumi Kogame, Hisanori Matsui
Publikováno v:
Biopharmaceutics & Drug Disposition. 41:283-294
TAK-448 is the investigational metastin/kisspeptin analog, which is known to have an anti-tumor effect through suppression of androgen hormones (luteinizing hormone and testosterone) levels. This study developed pharmacokinetic-pharmacodynamic (PK/PD
Publikováno v:
Xenobiotica. 49:833-839
Disposition of 2-(N-acetyl-d-tyrosyl-trans-4-hydroxy-l-prolyl-l-asparaginyl-l-threonyl-l-phenylalanyl) hydrazinocarbonyl-L-leucyl-Nω-methyl-l-arginyl-l-tryptophanamide monoacetate (TAK-448, RVT-602), a synthetic kisspeptin analog, was investigated a
Autor:
Sho Sato, Andy Sykes, Stuart Stafford, Yoshihiko Tagawa, Rosa Fradley, Shyam Bechar, Eimear Howley, Tomoki Yoneyama, Toshal Patel, Toshiya Moriwaki, Satoru Asahi
Publikováno v:
Pharmaceutical Research
Purpose TAK-831 is a highly selective and potent inhibitor of D-amino acid oxidase (DAAO) currently under clinical development for schizophrenia. In this study, a mechanistic multilayer quantitative model that parsimoniously connects pharmacokinetics
Autor:
Tamara J. van Steeg, Akihiko Goto, Takeshi Wakabayashi, Toshiya Moriwaki, Yoshihiko Tagawa, Joost DeJongh, Yoshiyuki Furukawa, Sho Sato, Tetsuya Tsukamoto, Yuu Moriya, Satoru Asahi
Publikováno v:
Biopharmaceutics & Drug Disposition. 38:373-380
In a dog toxicokinetic study, an unusual plasma concentration increase of the highly lipophilic compound TAK-357 was observed 2 weeks after termination of a 2-week repeated dosing in one dog with acute body weight loss. The present study investigates
Autor:
Tetsuya Tsukamoto, Yuu Moriya, Akihiko Goto, Takahiro Kondo, Takeshi Wakabayashi, T. Mandai, Satoru Asahi, Yoshihiko Tagawa
Publikováno v:
Drug Research. 67:38-45
The non-clinical pharmacokinetics (PK) of TAK-357, a highly lipophilic (clogP>6) potential agent for the amelioration of Alzheimer’s disease, was investigated in rats and dogs. A long half-life (t 1/2 ) in plasma was observed in animals and a low t
Publikováno v:
Biopharmaceutics & Drug Disposition. 37:467-478
The purpose of this study was to investigate the effect of the concentration-dependent erythrocyte distribution of TAK-802, a potent acetylcholinesterase inhibitor, on rat pharmacokinetics. In an ascending oral dose study, the maximum plasma concentr
Publikováno v:
Drug Metabolism and Disposition. 45:734-736
We evaluated the long-term stability of hepatocytes stored in the vapor phase of liquid nitrogen for their viability, cytochrome P450 (CYP) 1A2 activity, CYP3A4/5 activity, uridine diphosphate-glucuronosyl transferase (UGT) activity, sulfotransferase
Autor:
Kimio Tohyama, Toshiyuki Takeuchi, Akio Morohashi, Satoru Asahi, Naohiro Narita, Takahiro Kondo, Yoshihiko Tagawa
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 46(3)
N-{4-Chloro-2-[(1-oxidopyridin-4-yl)carbonyl]phenyl}-4-(propan-2-yloxy)benzenesulfonamide (MLN3126) is an orally available chemokine C-C motif receptor 9 selective antagonist. In nonclinical pharmacokinetic studies of MLN3126, nonextractable radioact
Autor:
Toshiyuki Takeuchi, Yoshihiko Tagawa, Takuya Ebihara, Rie Kadotani, Takahiro Kondo, Fumihiro Jinno, Yuu Moriya, Tomoo Itoh, Satoru Asahi
Publikováno v:
Biopharmaceutics & Drug Disposition. 34:236-246
Previous studies on the metabolic fate of resatorvid (TAK-242) have shown that species differences in the pharmacokinetics of 4-amino-3-chlorophenyl hydrogen sulfate (M-III), a metabolite of TAK-242, between rats and dogs are mainly attributable to t
Autor:
Wen Chyi Shyu, Akifumi Kogame, Satoru Asahi, Hideaki Tojo, Kimio Tohyama, Sachio Shibata, Shimoga R. Prakash, Yoshihiko Tagawa, Maki Miyamoto, Takahiro Kondo
Publikováno v:
Drug Metabolism and Disposition. 41:727-734
6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide (TAK-441) is a potent, selective hedgehog signaling pathway inhibitor that binds to Smo a